Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

BCR-ABL inhibitor HS-10382

An orally bioavailable, allosteric tyrosine kinase inhibitor of the BCR-ABL fusion oncoprotein, with potential antineoplastic activity. Upon oral administration, BCR-ABL inhibitor HS-10382 targets and binds to the ABL myristoyl pocket, locking BCR-ABL into an inactive conformation, thereby inhibiting the activity of BCR-ABL and decreasing the proliferation of tumor cells. BCR-ABL fusion protein is an aberrantly activated tyrosine kinase produced by certain leukemia cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:BCR-ABL tyrosine kinase inhibitor HS-10382
Code name:HS 10382
HS-10382
HS10382
TERN 701
TERN-701
TERN701
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search